21384-46-3Relevant articles and documents
Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors
Kaieda, Akira,Takahashi, Masashi,Takai, Takafumi,Goto, Masayuki,Miyazaki, Takahiro,Hori, Yuri,Unno, Satoko,Kawamoto, Tomohiro,Tanaka, Toshimasa,Itono, Sachiko,Takagi, Terufumi,Hamada, Teruki,Shirasaki, Mikio,Okada, Kengo,Snell, Gyorgy,Bragstad, Ken,Sang, Bi-Ching,Uchikawa, Osamu,Miwatashi, Seiji
, p. 647 - 660 (2018/01/03)
We identified novel potent inhibitors of p38 MAP kinase using structure-based design strategy. X-ray crystallography showed that when p38 MAP kinase is complexed with TAK-715 (1) in a co-crystal structure, Phe169 adopts two conformations, where one intera
Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists
Miwatashi, Seiji,Arikawa, Yasuyoshi,Matsumoto, Tatsumi,Uga, Keiko,Kanzaki, Naoyuki,Imai, Yumi N.,Ohkawa, Shigenori
experimental part, p. 1126 - 1137 (2009/09/25)
To investigate the potency of an adenosine A3 receptor (A 3AR) antagonist as an anti-asthmatic drug, a novel series of 4-phenyl-5-pyridyl-1,3-thiazole derivatives was synthesized and evaluated in human adenosine A1, A
MEDICINAL COMPOSITIONS
-
, (2008/06/13)
The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.